Tafenoquine
 | |
| Systematic (IUPAC) name | |
|---|---|
|
N-[2,6-Dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine | |
| Identifiers | |
| CAS Number |
106635-80-7  |
| ATC code | none |
| PubChem | CID 115358 |
| ChemSpider |
103196  |
| UNII |
262P8GS9L9 |
| ChEMBL |
CHEMBL298470 |
| NIAID ChemDB | 006901 |
| Synonyms | Etaquine,[1] WR 238605,[1] SB-252263 |
| Chemical data | |
| Formula | C24H28F3N3O3 |
| Molar mass | 463.493 g/mol |
| |
| |
| (what is this?) (verify) | |
Tafenoquine is an 8-aminoquinoline drug manufactured by GlaxoSmithKline that is being investigated as a potential treatment for malaria, as well as for malaria prevention.[2][3]
The proposed indication for tafenoquine is for treatment of the hypnozoite stages of Plasmodium vivax and Plasmodium ovale that are responsible for relapse of these malaria species even when the blood stages are successfully cleared. This is only now achieved by administration of daily primaquine for 14 days. The main advantage of tafenoquine is that it has a long half-life (2–3 weeks) and therefore a single treatment may be sufficient to clear hypnozoites. The shorter regimen has been described as an advantage.[4]
Like primaquine, tafenoquine causes hemolysis in people with G-6-P deficiency.[2] Indeed, the long half-life of tafenoquine suggests that particular care should be taken to ensure that individuals with severe G-6-P deficiency do not receive the drug.
The dose of tafenoquine has not been firmly established, but for the treatment of Plasmodium vivax malaria, a dose of 800 mg over three days has been used.[5]
References
- 1 2 Peters W (1999). "The evolution of tafenoquine--antimalarial for a new millennium?". J R Soc Med 92 (7): 345–352. PMC 1297286. PMID 10615272.
- 1 2 Shanks GD, Oloo AJ, Aleman GM, et al. (2001). "A New Primaquine Analogue, Tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria". Clin Infect Dis 33 (12): 1968–74. doi:10.1086/324081. JSTOR 4482936. PMID 11700577.
- ↑ Lell B, Faucher JF, Missinou MA, et al. (2000). "Malaria chemoprophylaxis with tafenoquine: a randomised study". Lancet 355 (9220): 2041–5. doi:10.1016/S0140-6736(00)02352-7. PMID 10885356.
- ↑ Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko DA, Edstein MD (November 2008). "The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific". Transactions of the Royal Society of Tropical Medicine and Hygiene 102 (11): 1095–101. doi:10.1016/j.trstmh.2008.04.024. PMID 18541280.
- ↑ Nasvelda P, Kitchener S. (2005). "Treatment of acute vivax malaria with tafenoquine". Trans R Soc Trop Med Hyg 99 (1): 2–5. doi:10.1016/j.trstmh.2004.01.013. PMID 15550254.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||